首页> 外文期刊>Drug research >Development and validation of liquid chromato-graphy-tandem mass spectrometric method for quantification of meropenem in rat plasma and its application in a preclinical dose proportionality study
【24h】

Development and validation of liquid chromato-graphy-tandem mass spectrometric method for quantification of meropenem in rat plasma and its application in a preclinical dose proportionality study

机译:液相色谱-串联质谱法在大鼠血浆中美罗培南定量的开发与验证及其在临床前剂量比例研究中的应用

获取原文
获取原文并翻译 | 示例
       

摘要

A simple, rapid, sensitive and selective assay based liquid chromatography-tandem mass spectrometric method was developed and validated for quantitative analysis of meropenem in rat plasma using rolipram as internal standard. Efficient chromatographic separation of analyte from matrix components was achieved by using Kromasil 100 C18 (150×4.6 mm, 5 μm) reversed phase column with mobile phase consisting of acetonitrile and 2 mM ammonium acetate buffer (80:20, v/v) delivered in isocratic mode with constant flow rate of 0.7 mL/min. Detection of meropenem and rolipram was performed in positive mode using multiple reaction monitoring (MRM). The mass transitions 384.1→141.0 and 276.2→191.1 were used to quantify meropenem and rolipram, respectively. A fast and simple solid phase extraction method was optimized for extraction of meropenem from rat plasma. The developed method was validated for selectivity, accuracy, precision, linearity, recovery, stability, matrix effect, dilution integrity as per regulatory guidelines. The developed method was selective with no interfering components at the retention time of meropenem and rolipram. The assay demonstrated acceptable linearity (R 20.99) over a dynamic range of 0.19-201.40 μg/mL. The method exhibited excellent and acceptable precision and accuracy, and produced consistent recoveries. The method demonstrated excellent stability of meropenem in rat plasma under studied conditions investigated. Finally, the validated method was successfully applied to quantify meropenem levels in rat plasma of a dose escalation study.
机译:建立了一种简单,快速,灵敏和选择性测定的液相色谱-串联质谱方法,并验证了使用咯利普兰作为内标的大鼠血浆中美罗培南的定量分析。通过使用Kromasil 100 C18(150×4.6 mm,5μm)反相色谱柱,流动相由乙腈和2 mM乙酸铵缓冲液(80:20,v / v)组成,可从基质组分中进行有效的色谱分离。等度模式,恒定流速为0.7 mL / min。使用多反应监测(MRM)以阳性模式进行美洛培南和咯利普兰的检测。质量变迁384.1→141.0和276.2→191.1分别用于定量美罗培南和咯利普兰。优化了一种快速简便的固相萃取方法,用于从大鼠血浆中提取美罗培南。根据法规指导,对开发的方法进行了选择性,准确性,精密度,线性,回收率,稳定性,基质效应,稀释完整性验证。所开发的方法具有选择性,在美罗培南和咯利普兰的保留时间内没有干扰组分。该测定在0.19-201.40μg/ mL的动态范围内显示可接受的线性(R 2> 0.99)。该方法显示出极好的和可接受的精度和准确性,并且产生了一致的回收率。该方法在研究的研究条件下证明了美罗培南在大鼠血浆中的优异稳定性。最后,经过验证的方法已成功地用于量化剂量升高研究中大鼠血浆中美罗培南的水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号